Amgen investors await weight-loss drug data
Amgen investors await weight-loss drug data
AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024
Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Sandoz, Amgen reach agreement resolving patent litigation over biosimilars
Sandoz reaches agreement with Amgen over patent dispute
Sandoz reaches agreement with Amgen over patent dispute
AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS
Amgen court hearing in patent lawsuit vs Sandoz over generic Prolia cancelled (update)
What's in the Cards for Amgen (AMGN) This Earnings Season?
What's in the Cards for Amgen (AMGN) This Earnings Season?
Insights Into Amgen (AMGN) Q1: Wall Street Projections for Key Metrics
Insights Into Amgen (AMGN) Q1: Wall Street Projections for Key Metrics
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
5 things to know before the stock market opens Monday
Manager of $100 million long/short fund explains pair trade strategy
Amgen to Seek European OK of Thyroid Eye Disease Drug Tepezza
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.